利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.052 秒)

    Curing light
    15.
    发明申请
    Curing light 有权
    固化光

    公开(公告)号：US20060024638A1

    公开(公告)日：2006-02-02

    申请号：US11173264

    申请日：2005-06-30

    申请人： Kenneth Rosenblood ,  Nancy Quan ,  Eric Rose

    发明人： Kenneth Rosenblood ,  Nancy Quan ,  Eric Rose

    IPC分类号： A61C3/00

    CPC分类号： A61C19/004 ,  A61K6/0643 ,  A61K6/08 ,  A61K8/19 ,  A61K8/20 ,  A61K8/21 ,  A61K8/24 ,  A61Q11/00 ,  Y10S362/80 ,  Y10S362/804 ,  C08L91/06

    摘要： The present invention relates to a curing light suitable for curing light curable dental composite materials. The curing light device has a light module housing having at least one heat sink located therein. The heat sink has at least two mounting platforms arranged in different geometric arrangements. More than two light sources may be used, emitting at least two different wavelengths. The curing light includes at least one heat sink having various geometric shapes, which facilitate the arrangement of the light sources in the curing light and minimizing the concentration.

    摘要翻译： 本发明涉及适用于固化光固化牙科复合材料的固化光。 固化灯装置具有其中具有至少一个散热器的光模块壳体。 散热器具有至少两个以不同的几何布置布置的安装平台。 可以使用两个以上的光源，发射至少两个不同的波长。 固化光包括具有各种几何形状的至少一个散热器，这便于在固化光中布置光源并使浓度最小化。

    High-profile mattress having an upper low-profile module with an air posturizing sleep surface
    16.
    发明授权
    High-profile mattress having an upper low-profile module with an air posturizing sleep surface 有权
    高调床垫具有上部低调模块，具有空气渗透性睡眠表面

    公开(公告)号：US06804848B1

    公开(公告)日：2004-10-19

    申请号：US10389173

    申请日：2003-03-14

    申请人： Eric Rose

    发明人： Eric Rose

    IPC分类号： A47C2710

    CPC分类号： A47C27/082 ,  A47C27/144 ,  A47C27/18 ,  A47C31/105

    摘要： A high-profile air sleep system is disclosed having an air posturizing sleep surface wherein the system comprises a base fabric cover layer, a plurality of resilient blocks overlying the base fabric cover layer, and a middle fabric cover layer overlying resilient blocks. A plurality of air chambers is carried above the middle fabric cover layer, and a resilient pad overlies the air chambers. A top fabric cover layer overlies the resilient pad. The foam blocks provide a cushion for the air chambers and the air chambers provide an upper air posturizing sleep surface. A first closure fasts the base cover layer and the middle cover layer; and a second closure fasts the middle cover layer and the top cover layer together whereby an integral high-profile sleep system is provided with an upper air sleep surface which can be adjusted to provide optimum sleep posture. The air posturizing air chambers are arranged side-by-side and generally coextend with the entirety of the middle, top, and base fabric cover layers.

    摘要翻译： 公开了一种具有空气刺激性睡眠表面的高调空气睡眠系统，其中系统包括基底织物覆盖层，覆盖在基底织物覆盖层上的多个弹性块和覆盖弹性块的中间织物覆盖层。 多个空气室被承载在中间织物覆盖层的上方，弹性垫覆盖在空气室上。 顶层织物覆盖层覆盖在弹性垫上。 泡沫块为空气室提供垫子，空气室提供上部空气刺激性睡眠表面。 第一个封盖使基部覆盖层和中间覆盖层更加牢固; 并且第二闭合件将中间覆盖层和顶盖层紧固在一起，由此整体式高轮廓睡眠系统设置有上部空气睡眠表面，其可以被调节以提供最佳的睡眠姿势。 空气促渗空气室并排布置，并且与中间，顶部和底部织物覆盖层的整体大致共同延伸。

    Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
    17.
    发明授权
    Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation 失效
    血液经受体外循环的患者血栓形成抑制方法

    公开(公告)号：US06391300B1

    公开(公告)日：2002-05-21

    申请号：US09192905

    申请日：1998-11-16

    申请人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

    发明人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

    IPC分类号： A61K3836

    CPC分类号： A61M1/3675 ,  A61K38/4846 ,  G01N33/86 ,  G01N2333/9645

    摘要： This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 &mgr;g/ml plasma to about 250 &mgr;g/ml plasma or from about 0.5 &mgr;g/ml plasma to about 25 &mgr;g/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The agent may be an active site-blocked Factor XII compound or an active site-blocked Factor XI compound.

    摘要翻译： 本发明提供了一种用于抑制血液经受体外血液循环的患者的血栓形成的方法，该方法包括使体外循环血液与因子IXa化合物以有效抑制患者血液中的血栓形成的量接触， 因子IXa化合物在患者体内循环。 因子IXa化合物可包括活性位点封闭的因子IXa化合物或Glu-Gly-Arg氯甲基酮灭活的人因子IXa化合物。 本发明还提供有效量可以为约0.1mug / ml血浆至约250mug / ml血浆或约0.5mug / ml血浆至约25mug / ml血浆。 患者可能在移植手术或心肺分流手术期间受到体外血液循环。 本发明还提供了一种用于抑制血液经受体外血液循环的患者的血栓形成的方法，其包括使体外循环血液与能够抑制凝固途径的步骤的试剂以有效抑制血栓形成的量接触 在患者的血液中和在因子IXa化合物在患者体内循环的条件下。 该试剂可以是活性位点封闭的因子XII化合物或活性位点封闭的因子XI化合物。

    Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
    18.
    发明授权
    Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation 失效
    血液经受体外循环的患者血栓形成抑制方法

    公开(公告)号：US5839443A

    公开(公告)日：1998-11-24

    申请号：US648561

    申请日：1996-05-16

    申请人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

    发明人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

    IPC分类号： A61K38/36 ,  A61K38/48 ,  A61M1/36 ,  G01N33/86 ,  A61B19/00

    CPC分类号： A61M1/3675 ,  A61K38/4846 ,  G01N33/86 ,  G01N2333/9645

    摘要： This invention provides an assay to monitor antithrombic activity of a Factor IXa compound infused into circulation of a patient which includes: (a) obtaining Factor IXa-deficient plasma; (b) mixing the plasma from step (a) with diatomaceous and with plasma from the patient; (c) incubating the mixture with a source of lipid and calcium chloride under conditions suitable for clot formation; and (d) measuring time necessary for clot formation in the incubate, thereby monitoring the antithrombic activity of the Factor IXa compound infused into the circulation of the patient.

    摘要翻译： 本发明提供了监测注射到患者循环中的因子IXa化合物的抗血栓活性的测定法，其包括：（a）获得因子IXa缺陷血浆; （b）将来自步骤（a）的血浆与硅藻土和来自患者的血浆混合; （c）在适合凝块形成的条件下将混合物与脂质和氯化钙源一起孵育; 和（d）测量培养物中凝块形成所需的时间，从而监测输注到患者循环中的因子IXa化合物的抗血栓活性。

    Pipelined processing of RDMA-type network transactions
    19.
    发明授权
    Pipelined processing of RDMA-type network transactions 有权
    流水线处理RDMA型网络交易

    公开(公告)号：US08078743B2

    公开(公告)日：2011-12-13

    申请号：US11356493

    申请日：2006-02-17

    申请人： Robert O. Sharp ,  Kenneth G. Keels ,  Brian S. Hausauer ,  Eric Rose

    发明人： Robert O. Sharp ,  Kenneth G. Keels ,  Brian S. Hausauer ,  Eric Rose

    IPC分类号： G06F15/16

    CPC分类号： H04L67/1097

    摘要： A computer system such as a server pipelines RNIC interface (RI) management/control operations such as memory registration operations to hide from network applications the latency in performing RDMA work requests caused in part by delays in processing the memory registration operations and the time required to execute the registration operations themselves. A separate QP-like structure, called a control QP (CQP), interfaces with a control processor (CP) to form a control path pipeline, separate from the transaction pipeline, which is designated to handle all control path traffic associated with the processing of RI control operations. This includes memory registration operations (MR OPs), as well as the creation and destruction of traditional QPs for processing RDMA transactions. Once the MR OP has been queued in the control path pipeline of the adapter, a pending bit is set which is associated with the MR OP. Processing of an RDMA work request in the transaction pipeline that has engendered the enqueued MR OP is permitted to proceed as if the processing of the MR OP has already been completed. If the work request gets ahead of the MR OP, the associated pending bit being set will notify the adapter's work request transaction pipeline to stall (and possibly reschedule) completion of the work request until the processing of the MR OP for that memory region is complete. When the memory registration process for the memory region is complete, the associated pending bit is reset and the adapter transaction pipeline is permitted to continue processing the work request using the newly registered memory region.

    摘要翻译： 计算机系统，例如服务器管线RNIC接口（RI）管理/控制操作，诸如存储器注册操作，以从网络应用中隐藏执行RDMA工作请求的延迟部分地由于处理存储器注册操作的延迟和所需的时间 执行注册操作本身。 称为控制QP（CQP）的独立QP类结构与控制处理器（CP）接口，以形成与事务流水线分开的控制路径流水线，其被指定为处理与处理相关联的所有控制路径流量 RI控制操作。 这包括内存注册操作（MR OP），以及创建和销毁用于处理RDMA事务的传统QP。 一旦MR OP已经在适配器的控制路径管道中排队，则设置与MR OP相关联的挂起位。 如果已经完成了MR操作的处理，处理已经引入入站的MR OP的事务流水线中的RDMA工作请求被执行。 如果工作请求超过MR OP，则相关的待处理位将被设置将通知适配器的工作请求事务流水线停止（可能重新计划）工作请求的完成，直到该存储器区域的MR OP的处理完成 。 当存储器区域的存储器注册过程完成时，相关联的挂起位被复位，并且适配器事务流水线被允许使用新登记的存储器区域继续处理工作请求。